---
pmid: '36217030'
title: A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19
  pathobiology and potential host therapeutic targets.
authors:
- Zhou Y
- Liu Y
- Gupta S
- Paramo MI
- Hou Y
- Mao C
- Luo Y
- Judd J
- Wierbowski S
- Bertolotti M
- Nerkar M
- Jehi L
- Drayman N
- Nicolaescu V
- Gula H
- Tay S
- Randall G
- Wang P
- Lis JT
- Feschotte C
- Erzurum SC
- Cheng F
- Yu H
journal: Nat Biotechnol
year: '2023'
full_text_available: false
pmcid: PMC9851973
doi: 10.1038/s41587-022-01474-0
---

# A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets.
**Authors:** Zhou Y, Liu Y, Gupta S, Paramo MI, Hou Y, Mao C, Luo Y, Judd J, Wierbowski S, Bertolotti M, Nerkar M, Jehi L, Drayman N, Nicolaescu V, Gula H, Tay S, Randall G, Wang P, Lis JT, Feschotte C, Erzurum SC, Cheng F, Yu H
**Journal:** Nat Biotechnol (2023)
**DOI:** [10.1038/s41587-022-01474-0](https://doi.org/10.1038/s41587-022-01474-0)
**PMC:** [PMC9851973](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851973/)

## Abstract

1. Nat Biotechnol. 2023 Jan;41(1):128-139. doi: 10.1038/s41587-022-01474-0. Epub 
2022 Oct 10.

A comprehensive SARS-CoV-2-human protein-protein interactome reveals COVID-19 
pathobiology and potential host therapeutic targets.

Zhou Y(#)(1), Liu Y(#)(2)(3), Gupta S(#)(2)(3)(4), Paramo MI(#)(2)(3)(5), Hou 
Y(#)(1), Mao C(6), Luo Y(6), Judd J(5), Wierbowski S(2)(3)(4), Bertolotti 
M(2)(3), Nerkar M(5), Jehi L(7), Drayman N(8), Nicolaescu V(9), Gula H(9), Tay 
S(10), Randall G(9), Wang P(11), Lis JT(5), Feschotte C(5), Erzurum SC(7), Cheng 
F(12)(13)(14), Yu H(15)(16)(17).

Author information:
(1)Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, 
Cleveland, OH, USA.
(2)Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, 
NY, USA.
(3)Center for Advanced Proteomics, Cornell University, Ithaca, NY, USA.
(4)Department of Computational Biology, Cornell University, Ithaca, NY, USA.
(5)Department of Molecular Biology and Genetics, Cornell University, Ithaca, NY, 
USA.
(6)Division of Health and Biomedical Informatics, Department of Preventive 
Medicine, Northwestern University, Chicago, IL, USA.
(7)Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
(8)Department of Molecular Biology and Biochemistry, University of California, 
Irvine, Irvine, CA, USA.
(9)Department of Microbiology, Ricketts Laboratory, University of Chicago, 
Chicago, IL, USA.
(10)Pritzker School of Molecular Engineering, University of Chicago, Chicago, 
IL, USA.
(11)Key Laboratory for Experimental Teratology of Ministry of Education and 
Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong 
University, Jinan, China.
(12)Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, 
Cleveland, OH, USA. chengf@ccf.org.
(13)Case Comprehensive Cancer Center, School of Medicine, Case Western Reserve 
University, Cleveland, OH, USA. chengf@ccf.org.
(14)Department of Molecular Medicine, Cleveland Clinic Lerner College of 
Medicine, Case Western Reserve University, Cleveland, OH, USA. chengf@ccf.org.
(15)Weill Institute for Cell and Molecular Biology, Cornell University, Ithaca, 
NY, USA. haiyuan.yu@cornell.edu.
(16)Center for Advanced Proteomics, Cornell University, Ithaca, NY, USA. 
haiyuan.yu@cornell.edu.
(17)Department of Computational Biology, Cornell University, Ithaca, NY, USA. 
haiyuan.yu@cornell.edu.
(#)Contributed equally

Update of
    Res Sq. 2022 Jun 07:rs.3.rs-1354127. doi: 10.21203/rs.3.rs-1354127/v2.

Studying viral-host protein-protein interactions can facilitate the discovery of 
therapies for viral infection. We use high-throughput yeast two-hybrid 
experiments and mass spectrometry to generate a comprehensive SARS-CoV-2-human 
protein-protein interactome network consisting of 739 high-confidence binary and 
co-complex interactions, validating 218 known SARS-CoV-2 host factors and 
revealing 361 novel ones. Our results show the highest overlap of interaction 
partners between published datasets and of genes differentially expressed in 
samples from COVID-19 patients. We identify an interaction between the viral 
protein ORF3a and the human transcription factor ZNF579, illustrating a direct 
viral impact on host transcription. We perform network-based screens of >2,900 
FDA-approved or investigational drugs and identify 23 with significant network 
proximity to SARS-CoV-2 host factors. One of these drugs, carvedilol, shows 
clinical benefits for COVID-19 patients in an electronic health records analysis 
and antiviral properties in a human lung cell line infected with SARS-CoV-2. Our 
study demonstrates the value of network systems biology to understand 
human-virus interactions and provides hits for further research on COVID-19 
therapeutics.

Â© 2022. The Author(s), under exclusive licence to Springer Nature America, Inc.

DOI: 10.1038/s41587-022-01474-0
PMCID: PMC9851973
PMID: 36217030 [Indexed for MEDLINE]

Conflict of interest statement: Competing interests The authors declare no 
competing interests.
